Stergios Boussios, Head of Department of Medical Oncology at University Hospital of Ioannina, shared a post on LinkedIn:
“Defective DNA repair is a hallmark of cancer – and a powerful therapeutic opportunity. From PARP inhibitors in BRCA-mutant cancers to emerging strategies exploiting synthetic lethality, resistance mechanisms, biomarkers, and novel combinations, this field is rapidly shaping the future of precision oncology.
Our upcoming special issue, “Targeting DNA Repair in Cancer”, welcomes original research, reviews, and perspectives that bridge basic mechanisms with clinical applications. Together with my colleague Panagiotis J. Vlachostergios, we are particularly interested in studies that investigate translational potential, mechanisms of resistance, the development of innovative biomarkers, and novel therapeutic combination strategies.
Join us at the Oncology Research journal your work and contribute to advancing precision medicine.”
More posts featuring Stergios Boussios.
